Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines

TY - JOUR

T1 - Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines

AU - Van Damme, Pierre

AU - Bonanni, Paolo

AU - Bosch, F Xavier

AU - Joura, Elmar A

AU - Krüger Kjaer, Susanne

AU - Meijer, Chris J L M

AU - Petry, Karl-Ulrich

AU - Soubeyrand, Benoit

AU - Verstraeten, Thomas

AU - Stanley, Margaret

PY - 2016/2/3

Y1 - 2016/2/3

N2 - With the availability of the nonavalent human papillomavirus (HPV) vaccine, vaccinees, parents and healthcare providers need guidance on how to complete an immunization course started with the bi- or quadrivalent vaccine and whether to revaccinate individuals who have completed a full immunization course with the bi- or quadrivalent vaccine. To answer these questions three parameters should be considered: age at the start of vaccination (9 to 14 years of age versus 15 years and older, the cut-off for 2 or 3 doses schedule), the number of doses already received and the time interval between doses. Based on a number of scenarios, we propose that the 9-valent vaccine can be used to complete an incomplete vaccination regimen or might be added to a previous completed schedule to extend protection.

AB - With the availability of the nonavalent human papillomavirus (HPV) vaccine, vaccinees, parents and healthcare providers need guidance on how to complete an immunization course started with the bi- or quadrivalent vaccine and whether to revaccinate individuals who have completed a full immunization course with the bi- or quadrivalent vaccine. To answer these questions three parameters should be considered: age at the start of vaccination (9 to 14 years of age versus 15 years and older, the cut-off for 2 or 3 doses schedule), the number of doses already received and the time interval between doses. Based on a number of scenarios, we propose that the 9-valent vaccine can be used to complete an incomplete vaccination regimen or might be added to a previous completed schedule to extend protection.

U2 - 10.1016/j.vaccine.2015.12.063

DO - 10.1016/j.vaccine.2015.12.063

M3 - Journal article

SN - 0264-410X

VL - 34

SP - 757

EP - 761

JO - Vaccine

JF - Vaccine

IS - 6

ER -